Advanced

Exocrine pancreatic function is preserved in systemic sclerosis

Bozovic, Gracijela LU ; Pullerits, Rille; Ståhl, Arne; Ydström, Kristina; Wenger, Daniel LU ; Marsal, Jan LU ; Thulin, Pontus and Andréasson, Kristofer LU (2019) In Arthritis Research & Therapy 21(1).
Abstract

BACKGROUND: Systemic sclerosis (SSc) has been suggested to cause exocrine pancreatic dysfunction. However, a case-control-based autopsy study failed to associate systemic sclerosis with any pancreatic histopathology. The primary objective of this study was to examine the exocrine pancreatic function in consecutive SSc patients in relation to an age- and sex-matched control group. A secondary objective was to relate exocrine pancreatic function to radiological, laboratory, and clinical SSc characteristics. METHODS: One hundred twelve consecutive patients fulfilling the 2013 American Congress of Rheumatology/European League Against Rheumatism criteria for SSc and 52 control subjects were matched for sex and age. Exocrine pancreatic... (More)

BACKGROUND: Systemic sclerosis (SSc) has been suggested to cause exocrine pancreatic dysfunction. However, a case-control-based autopsy study failed to associate systemic sclerosis with any pancreatic histopathology. The primary objective of this study was to examine the exocrine pancreatic function in consecutive SSc patients in relation to an age- and sex-matched control group. A secondary objective was to relate exocrine pancreatic function to radiological, laboratory, and clinical SSc characteristics. METHODS: One hundred twelve consecutive patients fulfilling the 2013 American Congress of Rheumatology/European League Against Rheumatism criteria for SSc and 52 control subjects were matched for sex and age. Exocrine pancreatic function was assessed by ELISA-based measurement of fecal elastase, and levels ≤ 200 μg/g were considered pathological, i.e., representing exocrine pancreatic insufficiency. Patients were characterized regarding SSc manifestations including gastrointestinal and hepatobiliary function, by use of laboratory and clinical examinations. Pancreas parenchyma characteristics were evaluated by high-resolution computer tomography (HRCT). RESULTS: A similar proportion of subjects exhibited pathological levels of fecal elastase among SSc patients (6/112; 5.4%) and control subjects (3/52; 5.8%). Patients with fecal elastase ≤ 200 μg/g did not differ from other SSc patients with respect to laboratory and clinical characteristics, including malnutrition. SSc subjects with low levels of fecal elastase displayed significantly lower pancreas attenuation on HRCT examinations compared to the control subjects. CONCLUSIONS: In this study encompassing 112 consecutive SSc patients and 52 matched control subjects, we were unable to associate systemic sclerosis with clinically significant exocrine pancreatic dysfunction.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Fecal elastase, Malnutrition, Pancreas, Systemic sclerosis
in
Arthritis Research & Therapy
volume
21
issue
1
pages
1 pages
publisher
BioMed Central
external identifiers
  • scopus:85061476394
ISSN
1478-6354
DOI
10.1186/s13075-019-1840-z
language
English
LU publication?
yes
id
53c38e53-72f7-49fd-b4f5-67bb61368641
date added to LUP
2019-02-21 11:15:07
date last changed
2019-05-24 03:00:22
@article{53c38e53-72f7-49fd-b4f5-67bb61368641,
  abstract     = {<p>BACKGROUND: Systemic sclerosis (SSc) has been suggested to cause exocrine pancreatic dysfunction. However, a case-control-based autopsy study failed to associate systemic sclerosis with any pancreatic histopathology. The primary objective of this study was to examine the exocrine pancreatic function in consecutive SSc patients in relation to an age- and sex-matched control group. A secondary objective was to relate exocrine pancreatic function to radiological, laboratory, and clinical SSc characteristics. METHODS: One hundred twelve consecutive patients fulfilling the 2013 American Congress of Rheumatology/European League Against Rheumatism criteria for SSc and 52 control subjects were matched for sex and age. Exocrine pancreatic function was assessed by ELISA-based measurement of fecal elastase, and levels ≤ 200 μg/g were considered pathological, i.e., representing exocrine pancreatic insufficiency. Patients were characterized regarding SSc manifestations including gastrointestinal and hepatobiliary function, by use of laboratory and clinical examinations. Pancreas parenchyma characteristics were evaluated by high-resolution computer tomography (HRCT). RESULTS: A similar proportion of subjects exhibited pathological levels of fecal elastase among SSc patients (6/112; 5.4%) and control subjects (3/52; 5.8%). Patients with fecal elastase ≤ 200 μg/g did not differ from other SSc patients with respect to laboratory and clinical characteristics, including malnutrition. SSc subjects with low levels of fecal elastase displayed significantly lower pancreas attenuation on HRCT examinations compared to the control subjects. CONCLUSIONS: In this study encompassing 112 consecutive SSc patients and 52 matched control subjects, we were unable to associate systemic sclerosis with clinically significant exocrine pancreatic dysfunction.</p>},
  author       = {Bozovic, Gracijela and Pullerits, Rille and Ståhl, Arne and Ydström, Kristina and Wenger, Daniel and Marsal, Jan and Thulin, Pontus and Andréasson, Kristofer},
  issn         = {1478-6354},
  keyword      = {Fecal elastase,Malnutrition,Pancreas,Systemic sclerosis},
  language     = {eng},
  month        = {02},
  number       = {1},
  pages        = {1},
  publisher    = {BioMed Central},
  series       = {Arthritis Research & Therapy},
  title        = {Exocrine pancreatic function is preserved in systemic sclerosis},
  url          = {http://dx.doi.org/10.1186/s13075-019-1840-z},
  volume       = {21},
  year         = {2019},
}